Comparative Pharmacology
Head-to-head clinical analysis: ADENOSINE versus NEXTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOSINE versus NEXTERONE.
ADENOSINE vs NEXTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is an endogenous purine nucleoside that acts as a non-selective agonist at adenosine A1, A2A, A2B, and A3 receptors. It slows atrioventricular (AV) conduction through activation of A1 receptors, which increases potassium efflux and reduces calcium influx, hyperpolarizing nodal cells and prolonging refractoriness. This terminates reentrant supraventricular tachyarrhythmias involving the AV node.
Class III antiarrhythmic agent; prolongs cardiac action potential duration by blocking potassium channels (IKr), primarily affecting the atria and ventricles.
Paroxysmal supraventricular tachycardia: 6 mg rapid IV bolus over 1-2 seconds; if no conversion in 1-2 minutes, give 12 mg rapid IV bolus; may repeat 12 mg once if necessary. Maximum single dose: 12 mg. Also used for cardiac stress testing: 140 mcg/kg/min IV infusion over 6 minutes, total dose 0.84 mg/kg.
Intravenous loading: 150 mg over 10 minutes, then 1 mg/min for 6 hours, followed by maintenance infusion of 0.5 mg/min. Oral: 400 mg twice daily for loading (total 1200 mg/day) for 7-10 days, then maintenance 200-400 mg once daily.
None Documented
Clinical Note
moderateCarbamazepine + Adenosine
"The risk or severity of adverse effects can be increased when Carbamazepine is combined with Adenosine."
Clinical Note
moderateTheophylline + Adenosine
"The therapeutic efficacy of Adenosine can be decreased when used in combination with Theophylline."
Clinical Note
moderateDyphylline + Adenosine
"The therapeutic efficacy of Adenosine can be decreased when used in combination with Dyphylline."
Clinical Note
moderateAminophylline + Adenosine
None Documented
Terminal elimination half-life <10 seconds (rapidly cleared from plasma by cellular uptake and metabolism); clinical context: transient effects require continuous IV infusion for sustained action.
Terminal elimination half-life of 58 days (range 25-110 days) due to extensive tissue distribution and slow release from lipid stores. Steady-state concentrations require approximately 3-6 months of chronic dosing.
Hepatic metabolism (primarily via adenosine deaminase and adenosine kinase) to inosine and AMP; renal excretion of metabolites accounts for <10% of elimination.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary excretion of metabolites is significant, with approximately 30-40% eliminated in feces. Renal excretion accounts for ~15-20% of total clearance as metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic
"The therapeutic efficacy of Adenosine can be decreased when used in combination with Aminophylline."